CCC
MRNA icon

Crescent Capital Consulting’s Moderna MRNA Stock Holding History

Crescent Capital Consulting’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3
Closed -$540K – 594
2021
Q2 		$540K Buy
+3
New +$536 0.1% 107

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Crescent Capital Consulting's MRNA Position: Q4 2021 in Review

Crescent Capital Consulting increased its Moderna (MRNA) stake by 18% in Q4 2021, buying an estimated $58.5K and bringing the position to 1,335 shares worth $339K. The position accounts for 0.06% of the portfolio, ranked #140.

Crescent Capital Consulting first reported a position in MRNA in Q4 2020 and has held it in 5 quarters since. The position peaked at $436K in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

  • Crescent Capital Consulting held 1,335 shares of Moderna worth $339K as of Q4 2021.
  • Crescent Capital Consulting bought 200 Moderna shares in Q4 2021, an estimated $58.5K.
  • Moderna made up 0.06% of Crescent Capital Consulting's portfolio in Q4 2021, its #140 holding.
  • Crescent Capital Consulting first reported a position in Moderna in Q4 2020 and has held it in 5 quarters since.
  • Crescent Capital Consulting's Moderna position peaked at $436K in Q3 2021.
  • 1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.